Summary of minutes of EUCAST Steering Committee Meeting
Linz, Austria 15-16 September 2014

### Attending
- Dr Derek F.J. Brown (DB) Scientific Secretary, United Kingdom
- Dr Karen Bowker (KB) BSAC, United Kingdom
- Dr Rafael Cantón (RC) Chairperson, Spain
- Prof Luc Dubreuil (LD) CA-SFM, France
- Dr Christian Giske (CG) SRGA, Sweden
- Prof Gunnar Kahlmeter (GK) Clinical Data Co-ordinator, Sweden
- Prof Johan W. Mouton (JM) CRG, The Netherlands
- Prof Sören Gatermann (SG) EUCAST General Committee, Germany
- Dr Martin Steinbakk (MS) NWGA, Norway
- Prof Jan Verhagen (JV) EUCAST General Committee, Belgium

### Apologies
- Prof Alasdair P. MacGowan (AM) BSAC, United Kingdom
- Dr Iztok Štrumbelj (IS) EUCAST General Committee, Slovenia

### Visiting members:
- Prof Petra Apfalter (PA) EUCAST General Committee, Austria
- Prof William Craig (WC) EUCAST General Committee, USA
- Dr Erika Matuschek (EM) EUCAST Method Development Laboratory, Sweden

### Present for item 21:
Company representatives

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chairman’s welcome</td>
</tr>
<tr>
<td>2</td>
<td>Minutes of meeting of 7-8 July 2014 With minor modifications, accepted as a correct record.</td>
</tr>
<tr>
<td>3</td>
<td>Matters arising from minutes of 7-8 July 2014 (items not covered by agenda) It was agreed to include expert rules in breakpoint tables.</td>
</tr>
<tr>
<td>4</td>
<td>New agents Antimycobacterial breakpoints will be included in a separate tab in the breakpoint tables. Breakpoint issues related to new oxazolidinone and glycopeptide agents. were discussed.</td>
</tr>
<tr>
<td>5</td>
<td>EUCAST rationale documents Old rationale documents will be updated to the current format. Ceftaroline and ceftobiprole documents are close to completion. Early drafts of macrolide documents are being revised before release. Aztreonam and chloramphenicol documents are at an early drafting stage. Some issues in the ampicillin, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole documents are to be resolved before release.</td>
</tr>
<tr>
<td>6</td>
<td>Subcommittees Antifungal susceptibility testing: E.Def 9.2 on MIC determination for moulds and itraconazole breakpoints for Candida spp. have been released on the EUCAST website.</td>
</tr>
</tbody>
</table>
| 7    | Breakpoint issues A note about the revised MIC method and breakpoints for telavancin has been released as an addendum to breakpoint tables. Following the wide consultation on ciprofloxacin breakpoints of S≤ 0.03, R >0.03 mg/L for Neisseria meningitidis, the new breakpoints will be included in breakpoint tables version 5.0. The WHO QC strain collection for N. gonorrhoeae (details in J Antimicrob Chemother 2009; 63: 1142-51) will be included in the EUCAST QC recommendations. Formation of an ESCMID study group on sexually transmitted infections is being investigated. For Acinetobacter spp., progress on sulbactam breakpoints is delayed by the absence of adequate MIC distributions. Cefoperazone-sulbactam breakpoints and a note on use of rifampicin in combined
therapy are being considered.

Protein binding and PD targets for colistin are being reassessed.

Carbapenem breakpoints are being reviewed.

Following wide consultation it was agreed that both staphylococci and streptococci will be reported resistant if dissociated resistance is detected.

EUCAST expert rules are being reviewed.

In the breakpoint tables it will be stated that oral treatment should be adequate for ampicillin/amoxicillin susceptible *S. pneumoniae* isolates but should be avoided for isolates with intermediate susceptibility.

Daptomycin breakpoints will be developed for enterococci.

Tigecycline breakpoints for Enterobacteriaceae are being reviewed.

Nitrofurantoin breakpoints for Enterobacteriaceae from uncomplicated UTI are being developed.

Temocillin breakpoints are being developed.

Correlation of ciprofloxacin and moxifloxacin MICs has been added to the website calibration file on *Corynebacterium* spp.

Guidelines on fosfomycin susceptibility testing are being prepared.

Establishment of a veterinary group on antimicrobial susceptibility testing is being examined.

It was agreed to start a review process for fluoroquinolone breakpoints for Enterobacteriaceae.

EUCAST breakpoint tables v. 5.0 were reviewed.

8 Organisms without EUCAST breakpoints Work is in progress on several groups of organisms.

9 EUCAST methods
Agents to test by the disk diffusion method were agreed for *Aerococcus* spp. and *Kingella kingae*.

The broth microdilution MIC determination service will be outlined on the EUCAST website.

10 Implementation of EUCAST breakpoints Implementation maps will be posted on the website with annual updates.

11 EUCAST websites
Website should be “marketed” to infectious diseases specialists, who may not be aware of the site.

Older versions of breakpoint tables and QC tables were on the website. All other old versions of documents are available on request.

It was agreed that it would be useful to include some website usage statistics.

12 Publications and presentations A paper on uptake of EUCAST breakpoints will be published in Euro Surveillance.

13 NACs No additional information.

14 EUCAST SOPs
Version 4.1 of SOP on EUCAST committees has been released.

SOP 9.0 on development of QC criteria and zone diameter breakpoints is close to completion.
| 15 | ESCMID | The deadline for abstracts for ECCMID 2015 is 30th October 2014. The Postgraduate Educational Course on antimicrobial susceptibility testing and resistance surveillance will be held in Linz, 16-19 September 2014. |
| 16 | EMA | Revision of the EMA-EUCAST SOP is expected soon. When changes are agreed to breakpoints previously set according to the EMA-EUCAST SOP, the EMA will be informed and they will act on changing breakpoints in SmPCs. |
| 17 | ECDC | A new call for tender for EUCAST is expected by the end of September 2014. |
| 18 | CLSI | No new information. |
| 19 | ECDC | Recommendations on generation and reporting of statistics on bacterial resistance It was agreed that this was an action area for ESGARS rather than EUCAST. |
| 20-22 | New glycopeptide agent | The agent was presented by the company and EUCAST has proposed breakpoints. |
| 23 | Any other business | None. |
| 24 | Next meetings | 10-11 November 2014, Basel, Switzerland. 16-17 February 2015, Leuven, Belgium. 28-29 April 2015, Copenhagen, Denmark (immediately following ECCMID). 13-14 July 2015, London, UK 7-8 September 2015, Stockholm, Sweden 9-10 November, 2015, venue to be decided 8-9 February 2016, venue to be decided |

Ratified summary of minutes of meeting 15-16 September 2014. Prepared by DB, RC and GK